Nalbuphine Hydrochloride is a synthetic mixed agonist-antagonist opioid analgesic — kappa-opioid receptor agonist with mu-opioid receptor antagonist activity. Manufactured to USP monograph specifications. Ceiling effect on respiratory depression makes it usefu…
| API name | Nalbuphine Hydrochloride |
| CAS Registry Number | 23277-43-2 |
| Therapeutic Category | Human APIs |
| API Technology | Synthetic / semi-synthetic (molecule-specific route) |
| Pharmacopoeial reference | USP · Ph. Eur. · IP · JP — per-buyer specification |
| Manufacturer | Longshine Boi-Tech Pvt. Ltd., Pune, India |
| Quality system | WHO-GMP · ISO 9001:2015 · ICH Q7 · ICH Q11 |
Nalbuphine Hydrochloride is a synthetic mixed agonist-antagonist opioid analgesic — kappa-opioid receptor agonist with mu-opioid receptor antagonist activity. Manufactured to USP monograph specifications. Ceiling effect on respiratory depression makes it useful for post-operative pain and obstetric analgesia where full mu-agonist safety margin is a concern. Not federally scheduled in US — state-level scheduling varies.
We supply Nalbuphine Hydrochloride to human apis buyers across 50+ countries — generic drug manufacturers, CDMOs, hospital pharmacies, research institutions, and contract formulators. Letter of Authorization referencing our active DMF / CEP is issued at no charge to qualified buyers for ANDA, IND, NDA, EU Marketing Authorisation, MHRA UKMA, ANVISA, PMDA, and other regulatory pathways.
Nalbuphine Hydrochloride is released against the buyer's chosen pharmacopoeia — USP, Ph. Eur., IP, or JP — with the destination market determining the default. The same lot can carry multiple pharmacopoeial certifications where the monographs align. Specification highlights routinely reported on each Certificate of Analysis (CoA) include:
Each Nalbuphine Hydrochloride batch ships with a full impurity profile — identified, qualified, and reported per ICH Q3A and Q3B guidelines. Process-related impurities are characterised in the DMF Restricted Part; degradation products are characterised through forced-degradation studies (acid, base, oxidation, thermal, photolysis) and reported in the stability dossier. ICH-compliant stability data is available on accelerated (40°C / 75% RH) and long-term (25°C / 60% RH or 30°C / 65% RH per ICH zone) conditions — typically 6 months accelerated and 24 to 36 months long-term depending on the molecule. Photostability per ICH Q1B option 2 is included.
Active regulatory dossiers maintained for Nalbuphine Hydrochloride (or compatible LoA support):
| Jurisdiction | Filing type | Documentation |
|---|---|---|
| United States | FDA Type II DMF | Letter of Authorization within 24 business hours; DMF number disclosed under MNDA |
| European Union | EDQM CEP or ASMF | CEP certificate or ASMF Restricted/Applicant's Part dossier |
| United Kingdom | MHRA UKMA / Windsor Framework | CEP-based recognition; UK-specific reference letter |
| Brazil | ANVISA RDC 359/2020 | Portuguese-language CMC package + reference letter |
| Canada | Health Canada DMF | Cross-reference of US FDA DMF |
| Japan | PMDA J-DMF | JP-grade release with Japanese-language label data |
| Korea | MFDS DMF | KP-grade release |
| GCC region | SFDA dossier support | Reference letters and CMC packages |
Each CoA carries the manufacturing date, batch number, retest date, and a QR-style traceability identifier linked to the batch manufacturing record. Per ICH Q7 requirements, retain samples are held for two years past the API expiry.